Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Fingolimod blocks immunosurveillance of myeloma and B-cell lymphoma resulting in cancer development in mice.

Literature DB >> 22383793

Fingolimod blocks immunosurveillance of myeloma and B-cell lymphoma resulting in cancer development in mice.

Kristina Berg Lorvik, Bjarne Bogen, Alexandre Corthay.

Abstract

Entities: Chemical Disease Species

Mesh：

Substances：

Year: 2012 PMID： 22383793 DOI： 10.1182/blood-2011-10-388892

Source DB: PubMed Journal: Blood ISSN： 0006-4971 Impact factor: 22.113

Keyword Cloud
Cited

× No keyword cloud information.

12 in total

1. The protumorigenic potential of FTY720 by promoting extramedullary hematopoiesis and MDSC accumulation.

Authors: Y Li; T Zhou; Y Wang; C Ning; Z Lv; G Han; J C Morris; E N Taylor; R Wang; H Xiao; C Hou; Y Ma; B Shen; J Feng; R Guo; Y Li; G Chen
Journal: Oncogene Date: 2017-02-20 Impact factor: 9.867

Review 2. Risk Mitigation Strategies for Adverse Reactions Associated with the Disease-Modifying Drugs in Multiple Sclerosis.

Authors: Adnan M Subei; Daniel Ontaneda
Journal: CNS Drugs Date: 2015-09 Impact factor: 5.749

3. SH2D2A modulates T cell mediated protection to a B cell derived tumor in transgenic mice.

Authors: Tone Berge; Ingrid Helene Bø Grønningsæter; Kristina Berg Lorvik; Greger Abrahamsen; Stine Granum; Vibeke Sundvold-Gjerstad; Alexandre Corthay; Bjarne Bogen; Anne Spurkland
Journal: PLoS One Date: 2012-10-29 Impact factor: 3.240

Review 4. The antineoplastic properties of FTY720: evidence for the repurposing of fingolimod.

Authors: Sathya Narayanan Patmanathan; Lee Fah Yap; Paul G Murray; Ian C Paterson
Journal: J Cell Mol Med Date: 2015-07-14 Impact factor: 5.310

Review 5. How Do CD4(+) T Cells Detect and Eliminate Tumor Cells That Either Lack or Express MHC Class II Molecules?

Authors: Ole Audun Werner Haabeth; Anders Aune Tveita; Marte Fauskanger; Fredrik Schjesvold; Kristina Berg Lorvik; Peter O Hofgaard; Hilde Omholt; Ludvig A Munthe; Zlatko Dembic; Alexandre Corthay; Bjarne Bogen
Journal: Front Immunol Date: 2014-04-15 Impact factor: 7.561

Fingolimod blocks immunosurveillance of myeloma and B-cell lymphoma resulting in cancer development in mice.

1. The protumorigenic potential of FTY720 by promoting extramedullary hematopoiesis and MDSC accumulation.

Review 2. Risk Mitigation Strategies for Adverse Reactions Associated with the Disease-Modifying Drugs in Multiple Sclerosis.

3. SH2D2A modulates T cell mediated protection to a B cell derived tumor in transgenic mice.

Review 4. The antineoplastic properties of FTY720: evidence for the repurposing of fingolimod.

Review 5. How Do CD4(+) T Cells Detect and Eliminate Tumor Cells That Either Lack or Express MHC Class II Molecules?

6. Interleukin-1 is required for cancer eradication mediated by tumor-specific Th1 cells.

7. CD4+ T-cell killing of multiple myeloma cells is mediated by resident bone marrow macrophages.

8. A model for cancer-suppressive inflammation.

9. Molecular profiling of tumor-specific T_H1 cells activated in vivo.

Review 10. Patient experience and practice trends in multiple sclerosis - clinical utility of fingolimod.

Fingolimod blocks immunosurveillance of myeloma and B-cell lymphoma resulting in cancer development in mice.

1. The protumorigenic potential of FTY720 by promoting extramedullary hematopoiesis and MDSC accumulation.

Review 2. Risk Mitigation Strategies for Adverse Reactions Associated with the Disease-Modifying Drugs in Multiple Sclerosis.

3. SH2D2A modulates T cell mediated protection to a B cell derived tumor in transgenic mice.

Review 4. The antineoplastic properties of FTY720: evidence for the repurposing of fingolimod.

Review 5. How Do CD4(+) T Cells Detect and Eliminate Tumor Cells That Either Lack or Express MHC Class II Molecules?

6. Interleukin-1 is required for cancer eradication mediated by tumor-specific Th1 cells.

7. CD4+ T-cell killing of multiple myeloma cells is mediated by resident bone marrow macrophages.

8. A model for cancer-suppressive inflammation.

9. Molecular profiling of tumor-specific TH1 cells activated in vivo.

Review 10. Patient experience and practice trends in multiple sclerosis - clinical utility of fingolimod.

9. Molecular profiling of tumor-specific T_H1 cells activated in vivo.